Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 5 of 2075 for:    ESTRADIOL

The Interaction Between Diabetes and Estradiol on Human Brain Metabolism in Postmenopausal Women (E2T2D)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03681691
Recruitment Status : Recruiting
First Posted : September 24, 2018
Last Update Posted : May 29, 2019
Sponsor:
Collaborator:
National Institute on Aging (NIA)
Information provided by (Responsible Party):
Wake Forest University Health Sciences

Brief Summary:
The primary aim of this study is to test whether type 2 diabetes interacts with estradiol on brain metabolism in vivo in humans. This will be accomplished by imaging brain metabolism using positron emission tomography before and after short-term administration of transdermal 17β-estradiol in 10 postmenopausal women with diabetes and 10 non-diabetic postmenopausal women.

Condition or disease Intervention/treatment Phase
Diabetes Type 2 Dementia Drug: Estradiol patch Phase 1

Detailed Description:
Epidemiological studies suggest there may be an interaction between type 2 diabetes and estrogen in postmenopausal women, such that diabetes may interact with estrogen levels over time to increase risk for dementia. The mechanism for this effect is now known. However, animal research suggests that it may occur through estrogen's effects on cellular metabolism of glucose and ketone bodies. The primary aim of this study is to test whether type 2 diabetes interacts with estradiol on brain metabolism in vivo in humans. This will be accomplished by imaging brain metabolism using positron emission tomography before and after short-term administration of transdermal 17β-estradiol in 10 postmenopausal women with diabetes and 10 non-diabetic postmenopausal women.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 20 participants
Allocation: Non-Randomized
Intervention Model: Parallel Assignment
Intervention Model Description: Primary Objective: The primary objective is to determine whether the effects of glucose and ketone body uptake to the brain in response to 8-week administration of transdermal 17β-estradiol differ in postmenopausal women with and without type 2 diabetes.
Masking: None (Open Label)
Primary Purpose: Other
Official Title: The Interaction Between Diabetes and Estradiol on Human Brain Metabolism in Postmenopausal Women
Actual Study Start Date : May 13, 2019
Estimated Primary Completion Date : December 2019
Estimated Study Completion Date : December 2019


Arm Intervention/treatment
Experimental: Post menopausal women with diabetes
8-week administration of transdermal 17β-estradiol (Climara) patch in postmenopausal women with type 2 diabetes
Drug: Estradiol patch
transdermal 17β-estradiol patch
Other Name: Climara patch

Experimental: Post menopausal women without diabetes
8-week administration of transdermal 17β-estradiol (Climara) patch in postmenopausal women without type 2 diabetes.
Drug: Estradiol patch
transdermal 17β-estradiol patch
Other Name: Climara patch




Primary Outcome Measures :
  1. Change in uptake of glucose and ketone bodies in whole brain and Alzheimer's disease-related regions of interest. [ Time Frame: Baseline and 8 weeks ]
    Brain metabolism will be measured using PET tracers to examine brain glucose uptake (FDG PET) and ketone body (acetoacetate) uptake (AcAc). PET imaging data are co-registered to T1 structural MRI data to conduct region-of-interest based analyses. Absolute global and regional uptake of FDG and AcAc tracers will be quantified, as well as uptake of AcAc relative to FDG to find potential regions of compensatory ketone use


Secondary Outcome Measures :
  1. Change in short-term memory and executive function composite scores. [ Time Frame: Baseline and 8 weeks ]
    A battery of cognitive tasks will be administered before and after estrogen administration. Composite z-scores will be calculated by calculating a z-score for each cognitive task and summing z-scores from -5 (low) to 5 (high) for the tasks designated as short-term memory and executive function.Higher scores denotes better outcomes.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   65 Years to 80 Years   (Older Adult)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  1. Willing to provide written informed consent
  2. Stated willingness to comply with all study procedures and availability for the duration of the study
  3. Female, postmenopausal, aged 65-80
  4. Normal results on recommended healthcare screenings (e.g., mammogram, pap smear, colonoscopy)
  5. BMI 20-30 kg/m2
  6. No evidence of dementia or mild cognitive impairment (MoCA score >25)
  7. Able to access reliable transportation to study and intervention visits

Exclusion Criteria:

  1. Use of hormone replacement therapy within the past 3 months
  2. History of renal, heart, liver, or neurological disease; head injury with loss of consciousness in the past 5 years; chronic pain, anxiety or depression
  3. Presence of medical conditions that might contraindicate estrogen use (e.g., unexplained vaginal bleeding, history of reproductive tissue cancer, thrombosis)
  4. Currently taking insulin, metformin, or any other drug or medication judged by the study physician to affect safety or research outcomes of interest
  5. Involved in another research study
  6. Contraindications for MRI or PET scanning
  7. Current smoker

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03681691


Contacts
Layout table for location contacts
Contact: Benita Bowman 336-713-5382 bmbowman@wakehealth.edu
Contact: Katie M Smith, CCRC 336 713-9375 kasmith@wakehealth.edu

Locations
Layout table for location information
United States, North Carolina
Wake Forest University Health Sciences Recruiting
Winston-Salem, North Carolina, United States, 27157
Contact: Benita Bowman    336-713-5382    bmbowman@wakehealth.edu   
Principal Investigator: Christina Hugenschmidt, PhD         
Sponsors and Collaborators
Wake Forest University Health Sciences
National Institute on Aging (NIA)
Investigators
Layout table for investigator information
Principal Investigator: Christina Hugenschmidt, PhD Wake Forest Health Sciences

Layout table for additonal information
Responsible Party: Wake Forest University Health Sciences
ClinicalTrials.gov Identifier: NCT03681691     History of Changes
Other Study ID Numbers: IRB00049740
R21AG054955 ( U.S. NIH Grant/Contract )
First Posted: September 24, 2018    Key Record Dates
Last Update Posted: May 29, 2019
Last Verified: May 2019
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Undecided
Plan Description: Undecided at the present time.

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Product Manufactured in and Exported from the U.S.: No
Keywords provided by Wake Forest University Health Sciences:
women's health
estradiol
postmenopausal
Additional relevant MeSH terms:
Layout table for MeSH terms
Estradiol 3-benzoate
Estradiol 17 beta-cypionate
Estradiol
Polyestradiol phosphate
Dementia
Diabetes Mellitus
Diabetes Mellitus, Type 2
Glucose Metabolism Disorders
Metabolic Diseases
Endocrine System Diseases
Brain Diseases
Central Nervous System Diseases
Nervous System Diseases
Neurocognitive Disorders
Mental Disorders
Estrogens
Hormones
Hormones, Hormone Substitutes, and Hormone Antagonists
Physiological Effects of Drugs
Contraceptive Agents
Reproductive Control Agents
Contraceptive Agents, Female